{"title":"Carbapenemase Detection Among Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates Using a Modified Blue-Carba Test","authors":"E. Tjoa, Shikha Joon, Dianita Angeline, Andrew A. Lieputra, Daniel Edbert, L. Moehario","doi":"10.35652/igjps.2022.12027","DOIUrl":null,"url":null,"abstract":"Objective:Acinetobacter baumanniiis a Gram-negative opportunistic bacteria with carbapenemase-associated antibiotic resistance accounting for a majority of nosocomial infections globally. We sought to detectcarbapenemase producers among carbapenem-resistant A. baumannii(CRAB) clinical isolates using Blue-Carba Test(BCT).Methods: This study was an observational descriptive study. At first, A. baumanniiclinical isolates (142) were collected from January 2014 to September 2017and stored at the Microbiology Laboratoryof the Faculty of Medicine, Atma Jaya Hospital. Next step involved the identification of the carbapenem-resistant isolates using WHONET 5.3 software (https://whonet.org/software.html). Here, Imipenem and Meropenem served as markers. Finally, the identified carbapenem-resistant isolates were subjected to Blue-Carba Test. Results: Among 142 A. baumannii isolates, 51.4% (73/142) were identified as CRAB. Of these, 36 isolates were revived and all were found to be carbapenemase positive. Conclusion: Conclusively, a cent percent (36/36) prevalence of carbapenemase producers was observed in the CRAB group, which is an important clinical finding for antibiotic selection against A. baumannii infection.©2022iGlobal Research and PublishingFoundation. All rights reserved.","PeriodicalId":13366,"journal":{"name":"Indo Global Journal of Pharmaceutical Sciences","volume":"133 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indo Global Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35652/igjps.2022.12027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
改良蓝碳法检测耐碳青霉烯类鲍曼不动杆菌临床分离株碳青霉烯酶
目的:鲍曼不动杆菌是一种革兰氏阴性机会性细菌,具有碳青霉烯酶相关的抗生素耐药性,占全球医院感染的大多数。我们试图用蓝碳试验(BCT)检测耐碳青霉烯类鲍曼不动杆菌(CRAB)临床分离株中碳青霉烯酶的产生物。方法:本研究为观察性描述性研究。首先于2014年1月至2017年9月收集鲍曼单胞杆菌临床分离株(142株),保存于Atma Jaya医院医学院微生物实验室。下一步是使用WHONET 5.3软件(https://whonet.org/software.html)鉴定碳青霉烯类耐药菌株。这里,亚胺培南和美罗培南作为标记物。最后,对鉴定出的碳青霉烯类耐药菌株进行Blue-Carba试验。结果:142株鲍曼不动杆菌中,鉴定为CRAB的占51.4%(73/142)。其中,36株菌株被复活,所有菌株都呈碳青霉烯酶阳性。结论:螃蟹组碳青霉烯酶产生菌的发生率为1%(36/36),这对鲍曼不饱和杆菌感染的抗生素选择具有重要的临床意义。©2022全球研究与出版基金会。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。